Phospho-PPP2CA (Y307) Recombinant Monoclonal Antibody

說明書

中文名稱：

磷酸化-PPP2CA (Y307)重組抗體
貨號(hào)：

CSB-RA018559A307phHU
規(guī)格：

￥1320
圖片：
Western Blot
Positive WB detected in A549 whole cell lysate(treated with EGF or not)
All lanes Phospho-PPP2CA antibody at 0.95μg/ml
Secondary
Goat polyclonal to rabbit IgG at 1/50000 dilution
Predicted band size: 35 KDa
Observed band size: 35 KDa
其他：

產(chǎn)品詳情
產(chǎn)品評(píng)價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

產(chǎn)品描述：

CSB-RA018559A307phHU重組單克隆抗體是針對(duì)PPP2CA蛋白Y307磷酸化位點(diǎn)開發(fā)的高特異性科研試劑。PPP2CA作為蛋白磷酸酶PP2A的核心催化亞基，通過去磷酸化作用調(diào)控細(xì)胞周期進(jìn)程、DNA損傷應(yīng)答及多種信號(hào)通路活性，其Y307位點(diǎn)的磷酸化修飾可顯著影響酶活性和底物特異性。本產(chǎn)品經(jīng)ELISA和蛋白質(zhì)印跡（WB）嚴(yán)格驗(yàn)證，在1:500至1:5000稀釋范圍內(nèi)能穩(wěn)定檢測(cè)內(nèi)源性磷酸化PPP2CA，適用于檢測(cè)細(xì)胞裂解液、組織樣本等不同來源的生物學(xué)標(biāo)本。該抗體可廣泛應(yīng)用于探索PP2A在腫瘤發(fā)生、神經(jīng)退行性疾病及代謝調(diào)控中的分子機(jī)制研究，特別適用于磷酸化依賴性蛋白相互作用分析、激酶/磷酸酶信號(hào)網(wǎng)絡(luò)研究以及相關(guān)疾病模型的分子病理探索。采用重組單克隆抗體技術(shù)制備，具有高批次間一致性和低交叉反應(yīng)性，為磷酸化修飾調(diào)控的靶點(diǎn)研究提供可靠工具。
Uniprot No.：

P67775
基因名：

PPP2CA
別名：

PP2A A antibody; PP2A alpha antibody; PP2A B antibody; PP2A beta antibody; PP2A-alpha antibody; PP2A-beta antibody; PP2AA_HUMAN antibody; PP2Aalpha antibody; PP2AB_HUMAN antibody; PP2Abeta antibody; PP2Ac antibody; PP2CA antibody; PP2Calpha antibody; PP2CB antibody; PPP2CA antibody; PPP2CB antibody; Protein phosphatase 2 catalytic subunit alpha isoform antibody; Protein phosphatase 2 catalytic subunit beta isoform antibody; Protein phosphatase type 2A catalytic subunit antibody; Replication protein C antibody; RP C antibody; RP-C antibody; RPC antibody; Serine/threonine protein phosphatase 2A catalytic subunit alpha isoform antibody; Serine/threonine protein phosphatase 2A catalytic subunit beta isoform antibody; Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform antibody
反應(yīng)種屬：

Human
免疫原：

A synthesized peptide derived from Human Phospho-PPP2CA (Y307)
免疫原種屬：

Homo sapiens (Human)
標(biāo)記方式：

Non-conjugated
克隆類型：

Monoclonal
抗體亞型：

Rabbit IgG
純化方式：

Affinity-chromatography
克隆號(hào)：

3F11
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA, WB

推薦稀釋比：

Application	Recommended Dilution
WB	1:500-1:5000

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
儲(chǔ)存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

功能：

PP2A is the major phosphatase for microtubule-associated proteins (MAPs). PP2A can modulate the activity of phosphorylase B kinase casein kinase 2, mitogen-stimulated S6 kinase, and MAP-2 kinase. Cooperates with SGO2 to protect centromeric cohesin from separase-mediated cleavage in oocytes specifically during meiosis I. Can dephosphorylate SV40 large T antigen and p53/TP53. Activates RAF1 by dephosphorylating it at 'Ser-259'. Mediates dephosphorylation of WEE1, preventing its ubiquitin-mediated proteolysis, increasing WEE1 protein levels, and promoting the G2/M checkpoint. Mediates dephosphorylation of MYC; promoting its ubiquitin-mediated proteolysis: interaction with AMBRA1 enhances interaction between PPP2CA and MYC. Mediates dephosphorylation of FOXO3; promoting its stabilization: interaction with AMBRA1 enhances interaction between PPP2CA and FOXO3.
基因功能參考文獻(xiàn)：
1. High PP2A expression is associated with Colorectal Cancer Cell Invasiveness. PMID: 30275201
2. PP2A overexpression is associated with lung metastasis in colorectal cancer . PMID: 30144452
3. Suspension survival mediated by PP2A-STAT3-Col XVII determines tumor initiation and metastasis in cancer stem cells. PMID: 27306323
4. alpha-Syn bound to PP2A Calpha by the hydrophobic interaction and upregulated its activity. Blocking the hydrophobic domain of alpha-Syn or hydrophilic mutation on the residue I123 in PP2A Calpha all reduced PP2A activity upregulation by alpha-Syn. PMID: 29996119
5. The results showed SNPs near PPP2CA were associated with decreased expression of PPP2CA mRNA in PBMCs from patients with SLE and suggested that the mRNA expression of the gene may be correlated with the pathogenesis of SLE. PMID: 28144936
6. This study demonstrated an association of PPP2CA (rs10491322 and rs7704116) with systemic lupus erythematosus susceptibility in a Chinese Han population. Furthermore, the minor allele of PPP2CA rs10491322 as a risk factor was correlated with immunologic disorders for systemic lupus erythematosus. PMID: 29979448
7. RAB9 competes with the catalytic subunit PPP2CA in binding to PPP2R1A. This competitive association has an important role in controlling the PP2A catalytic activity. PMID: 27611305
8. Results show that miR-199b is a tumor suppressor emerges as a potential contributing mechanism to inhibit PP2A via PP2A inhibitor SET (SET) overexpression in metastatic colorectal cancer (mCRC). PMID: 27517624
9. Data show that protein phosphatase-2A (PP2A) was upregulated in lung adenocarcinoma cell lines that were transfected with midline 1 E3 ubiquitin-protein ligase (MID1)-siRNA, suggesting MID1 negatively regulates PP2A in lung adenocarcinoma. PMID: 29450633
10. B55alpha-PP2A mutations in acute myeloid leukemia have roles in leukemogenesis by promoting AKT T308 phosphorylation and sensitivity to AKT inhibitor-induced growth arrest PMID: 27531894
11. This work has significantly advanced our understanding of the RACK1/PP2A complex and suggests a pro-carcinogenic role for the RACK1/PP2A interaction. This work suggests that approaches to target the RACK1/PP2A complex are a viable option to regulate PP2A activity and identifies a novel potential therapeutic target in the treatment of breast cancer. PMID: 27600565
12. Moreover, PP2Acalpha2-overexpressed cells demonstrated increased expression of IGBP1, activated mTORC1 signaling to reduce basal autophagy and increased anchorage-independent growth. Our study provides new insights into the complex mechanisms of PP2A regulation. PMID: 29066346
13. protein phosphatase 2A (PP2A)-mediated Raf-MEK-ERK signaling was involved in glutaminolysis in endothelial cells. PMID: 27612201
14. Studies indicate that protein phosphatase methylesterase-1 (PME-1) negatively regulates protein phosphatase 2A (PP2A) activity by highly complex mechanisms. PMID: 27913678
15. Binding of PP2A and Akt increased in response to cAMP or phosphatidic acid (PA), suggesting that their binding is directly responsible for the inactivation of Akt during decidualization. PMID: 27696687
16. Knockdown of Alpha4 preferentially impacts the expression of PP4c and PP6c compared to expression levels of PP2Ac. PMID: 27169767
17. these data support a role for the novel PP2Ac-CIN85 complex in supporting integrin-dependent platelet function by dampening the phosphatase activity. PMID: 27334924
18. PP2Ac upregulation has a poor prognostic impact on the overall survival of hepatocellular carcinoma (HCC) patients and contributes to the aggressiveness of HCC. PP2Ac may represent a potential therapeutic target for HCC. PMID: 26618405
19. Data show that downregulating proto-oncogene protein Akt (p-Akt) by inhibiting PP2A inhibitor SET-mediated protein phosphatase 2A (PP2A) inactivation determined the pro-apoptotic effects of EMQA and paclitaxel combination treatment. PMID: 26575017
20. Data suggest a critical role for the I2PP2A protein (SET)-protein phosphatase-2A (PP2A) signaling axis in Pten protein (Pten) deficient castration resistant prostate cancer (CRPC) progression. PMID: 26563471
21. that loss of glucocerebrosidase function may contribute to SNCA accumulation through inhibition of autophagy via PPP2A inactivation PMID: 26378614
22. Data show that loss of epithelial membrane protein 2 (EMP2) is involved in sphingosylphosphorylcholine (SPC)-induced phosphorylation of keratin 8 (K8) via ubiquitination of protein phosphatase 2 (PP2A) through alpha4 phosphoprotein by caveolin-1 (cav-1). PMID: 26876307
23. Data show that the protein phosphatase 2A (PP2A)/c-jun N-Terminal Kinase (JNK)/Sp1 transcription factor/CDK1 kinase pathway and the autophagy/cyclin kinase inhibitor p21 pathway participated in G2/M cell cycle arrest triggered by PP2A inhibitors. PMID: 26053095
24. Data indicate that LB100 attenuates protein phosphatase 2A (PP2A) activity alone and following radiation. PMID: 25939762
25. Concurrent mTORC1 inactivation and PP2A-B55alpha stimulation fuel ULK1-dependent autophagy. PMID: 26310906
26. Data show that the biogical effect of inhibitor-2 of protein phosphatase-2A (SET) on proliferation and invasion was mediated by the inhibition of the protein phosphatase 2A (PP2A). PMID: 25945834
27. Binding of calmodulin changes the calcineurin regulatory region to a less dynamic conformation. PMID: 25956027
28. MID1 catalyzes the ubiquitination of protein phosphatase 2A and mutations within its Bbox1 domain disrupt polyubiquitination of alpha4 but not of PP2Ac in X-linked Opitz syndrome. PMID: 25207814
29. Mutations in the structurally buried D38 residue of PP2Calpha (PPM1A) redefined the water-mediated hydrogen network in the active site and selectively disrupted M2 metal ion binding. PMID: 25708299
30. possible role of an miR-155-PP2Ac loop in regulating IL-2 release PMID: 25253569
31. Increased PP2A activity and reduced phosphorylation of PP2A were observed in alpha-synuclein overexpression primary cortex neurons. PMID: 25567480
32. Idiopathic pulmonary fibrosis fibroblast interaction with polymerized type I collagen results in an aberrant PP2A/HDAC4 axis, which suppresses miR-29, causing a pathologic increase in type I collagen expression. PMID: 25612003
33. Alterations affecting PP2A subunits together with the deregulation of endogenous PP2A inhibitors such as CIP2A and SET have been described as contributing mechanisms to inactivate PP2A in prostate cancer. PMID: 26234767
34. GSK-3b and PP2A regulate each other and control tau phosphorylation both directly and indirectly through each other. PMID: 25219467
35. Reduced expression of PP2A/PR65 in ameloblastoma compared with normal oral mucosa indicates that PP2A/PR65 is involved in the occurrence and development of ameloblastoma. PMID: 24054836
36. HSP105 depletion disrupts the integration of protein phosphatase 2A into the beta-catenin degradation complex, favoring the hyperphosphorylation and degradation of beta-catenin. PMID: 25645927
37. Data suggest that expression of PP2A (protein phosphatase 2 catalytic subunit alpha) and PTEN (phosphatase and tensin homolog) is down-regulated in adenomyosis as compared to normal endometrium; expression of survivin appears to be up-regulated. PMID: 25152517
38. Studies indicate that oncoprotein CIP2A (KIAA1524) controls oncogenic cellular signals by suppressing protein phosphatase 2A (PP2A). PMID: 25015035
39. Findings suggest the possible contribution of SET protein to the tumor progression and the utility of protein phosphatase 2A (PP2A) activator, FTY720 for treatment of alveolar soft part sarcoma (ASPS). PMID: 24621013
40. this study suggests that the tightly linked regulatory loop comprised of the SIK2-PP2A and CaMKI and PME-1 networks may function in fine-tuning cell proliferation and stress response. PMID: 24841198
41. These results suggest that the aberrant expression of PP2A in human clear cell renal cell carcinoma PMID: 24696731
42. decreased eEF2 phosphorylation, mediated by increased PP2A activity, contributes to resistance to HER2 inhibition and may provide novel targets for therapeutic intervention in HER2 positive breast cancer which is resistant to HER2 targeted therapies. PMID: 24958351
43. PPP2AC activity is required for SREBP-2 DNA binding. PMID: 24770487
44. Phosphorylated PP2A is an alteration that determines poor outcome in metastatic colorectal cancer. PMID: 25003662
45. the alpha4 N-terminus binding to endogenous PP2Ac and PABP, and the C-terminus to EDD, is reported. PMID: 24145130
46. Our findings suggest that PPP2CA downregulation serves as a molecular link between gain of castration-resistance and aggressive PCa phenotype, and its restoration could be an effective preventive/therapeutic approach against the advanced disease. PMID: 24642616
47. This result combined with a number of biophysical analyses provide evidence that the coiled coil domain of striatin 3 and the PP2A A subunit form a stable core complex with a 2:2 stoichiometry PMID: 24550388
48. Inhibition of PP2A by okadaic acid curtailed the free fatty acids induced upregulation of SREBP1 expression, fatty acid synthase promoter transcriptional activity and lipid accumulation in HepG2 cells PMID: 23184344
49. PP2A constitutively dephosphorylates dCK in cells and negatively regulates its activity. PMID: 24462681
50. Data indicate that TCDD or omeprazole caused protein phosphatase 2A (PP2A)-mediated dephosphorylation of Sp1 transcription factor at Ser-59 and induced CYP1A1 transcription. PMID: 24382322
顯示更多

收起更多
亞細(xì)胞定位：

Cytoplasm. Nucleus. Chromosome, centromere. Cytoplasm, cytoskeleton, spindle pole.
蛋白家族：

PPP phosphatase family, PP-1 subfamily
數(shù)據(jù)庫鏈接：

HGNC: 9299

OMIM: 176915

KEGG: hsa:5515

STRING: 9606.ENSP00000418447

UniGene: Hs.105818

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
VIM Recombinant Monoclonal Antibody

Applications: ELISA, IHC, IF

Species Reactivity: Human
VDR Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human